Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
In the developing pharma landscape, it’s important to consider all variables to create a winning portfolio strategy. To support the development of your own successful portfolio strategy, Pharma Intelligence invites you to watch our webinar: “Where is the pharma industry maximizing value?”, filmed on Tuesday May 23, 2017, presented by Datamonitor Healthcare Principal Analyst, Amanda Micklus.
This webinar focuses on the state of the pharma industry regarding long-term portfolio planning from the R&D stage through externalization and commercialization. Covered topics include:
Business development trends, including - internal R&D spending (including productivity measurements). What are the factors contributing to the projected sharp CAGR decline through 2020? Who shows most success with new product launches, and why?
Licensing and deal-making - How does pharma complement internal R&D with external business development deals? Find out by volume, value, phase, and therapy area.
Revenue trends – How do we view R&D investment and licensing/deal-making through the lens of revenue? Compare companies in Big Pharma, Mid Pharma, and Japan Pharma in terms of internal R&D product revenue versus that from external products.
Datamonitor Healthcare: data analysis and insight, Biomedtra...
As the biopharma industry concludes its annual pilgrimage to San Francisco for the JP Morgan investor conference, much of the talk around town inevitably was about gene therapies.
Topics Cell and gene therapy
Datamonitor Healthcare: data analysis and insight, Biomedtra...
Commentators at the ISPOR Europe 2019 conference in Copenhagen debated the challenges that exist with valuing and financing potentially curative treatments, including cell and gene therapies, and cancer immunotherapies. With several recent regulatory approvals of high-cost advanced therapy medicinal products (ATMPs), discussion has ensued in earnest on how to determine their clinical value, and whether traditional reimbursement and health technology assessment (HTA) processes are sufficient to assess these innovative treatments.
Datamonitor Healthcare: data analysis and insight
By Joseph Haas
Non-alcoholic steatohepatitis (NASH) is poised to become an even greater epidemic and pharma companies of all sizes are competing to be the first to bring a NASH drug to market. Listen to an in-depth discussion about new and repurposed drug exploration treat NASH, as well as deal making, licensing and partnerships activity for the area.
Topics Cell and gene therapy Drug Development Landscape Drug approval
Request a Demo
Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.
Request live demo now:
How can we help you?
Our team is always happy to hear from you. Please call us at:
Pharma Report Store
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now:
Trialtrove is the go-to resource for clinical trial research. Easily track your competitors' clinical R&D activity with expert insights and continually monitored trials.
Biomedtracker provides real-time analysis of major market-moving events in the pharma and biotech industries. With catalyst tracking and expert insights, you stay on top of breaking events, what’s in the drugs pipeline, upcoming milestones, clinical trial results and their impact on the markets you care about
Understand what’s happening in the market right now and what it means for the future of your business with news and insight from our team of journalists and analysts. Scrip is essential for anyone making commercial decisions in the pharmaceutical industry.
Looking for more products Product Finder
